| Nasdaq: DYAX
Dyax Corp. is a biopharmaceutical company, which discovers, develops and commercializes biopharmaceuticals for unmet medical needs. The company utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. It also develops angioedema portfolio for the prophylactic treatment of hereditary angioedema and a diagnostic test to identify plasma kallikrein-mediated disorders. Dyax was founded in 1995 and is headquartered in Burlington, MA.